What factors influence your decision regarding whether to administer a dose-dense chemotherapy regimen in the adjuvant setting to patients with hormone-receptor postive disease?
Data presented at the 2017 SABCS (abstract GS1-01) of the EBCTCG meta-analysis stating a benefit of dose-dense chemotherapy applies to ER positive and negative patients seems to conflict with prior data reflected in a 2015 meta-analysis of >17,000 patients (Petrelli et al. Breat Cancer Reserach & Treatment 2015) which found the OS benefit was not seen in ER positive patients (HR 0.93, 95% CI 0.82-1.05, p=0.25).
2 Answers
Mednet MemberInvited Expert
Medical Oncology · H Lee Moffitt Cancer Center, University of South Florida
Answered on · Updated on
Many of the studies included in the analyses treated ER+ cases that we would call lower risk using modern genomic testing with adjuvant chemotherapy. So the observed effect of chemotherapy on recurrence and OS in ER+ disease can vary from study to study, depending on the numbers of low vs high risk ...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · University of California Irvine Medical Center
Answered on
The disparate results in the two meta-analysis can also be explained by the larger numbers in the current meta-analysis. Moreover, studies with longer follow up are needed in HR-positive breast cancer to evaluate the efficacy of a given chemotherapy with its ovarian function effect.
Join for free or sign in to see the full answer